雌四醇15 mg/屈螺酮3 mg周期方案治疗子宫内膜异位症相关疼痛及客观妇科所见的多中心安慰剂对照双盲随机研究:疗效与安全性
本研究为日本25个中心、162例子宫内膜异位症患者的24周随机双盲安慰剂对照平行组研究,评估雌四醇15 mg/屈螺酮3 mg周期给药(24天用药+4天安慰剂)6个周期的疗效与安全性。结果显示E4/DRSP组最严重盆腔痛VAS评分较基线下降33.2 mm,组间差异为-8.5 mm(95%CI -16.1至-0.9 mm),优于安慰剂;客观妇科所见显著改善,未观察到安全性担忧。
要点
- E4/DRSP周期方案治疗6个周期后最严重盆腔痛VAS评分较基线下降33.2 mm,组间差异-8.5 mm(95%CI -16.1至-0.9 mm),优于安慰剂。
- E4/DRSP组VAS评分较基线下降≥30%和≥50%的应答者比例分别为53.2%和36.4%,高于安慰剂组的29.6%和12.3%。
- E4/DRSP治疗显著改善客观妇科所见(子宫直肠陷凹硬结、盆腔压痛、子宫活动受限),未观察到安全性担忧。
核心结论
- 雌四醇/屈螺酮可有效治疗子宫内膜异位症相关疼痛并改善妇科所见。
- 雌四醇/屈螺酮可能是治疗子宫内膜异位症的一种安全新选择,且可能降低血栓栓塞事件风险。
研究设计与样本
- 24周、多中心、随机、双盲、安慰剂对照、平行组研究,纳入162例子宫内膜异位症日本女性,随机分配至E4/DRSP组或安慰剂组。
- E4/DRSP组每日口服1片含E4 15 mg和DRSP 3 mg的片剂,连续24天,随后服用1片安慰剂4天作为无激素间期,构成1个周期方案;安慰剂组每日服用1片安慰剂,连续28天。
- 治疗持续6个周期(24周),贯穿确证期。
主要发现
- E4/DRSP组最严重盆腔痛(下腹痛和背痛)VAS评分从基线至6周期治疗结束时平均变化为-33.2 mm,组间差异显著(-8.5 mm;双侧95%CI -16.1至-0.9 mm),显示优于安慰剂。
- E4/DRSP组VAS评分较基线下降≥30%和≥50%的应答者比例分别为53.2%和36.4%,安慰剂组分别为29.6%和12.3%。
- E4/DRSP治疗显著改善客观妇科所见(子宫直肠陷凹硬结、盆腔压痛和子宫活动受限),稳定和恶化参与者比例显著低于安慰剂组。
- E4/DRSP缩小子宫内膜瘤尺寸,并基于生活质量相关问卷和整体印象评分改善生活质量。
- E4/DRSP治疗未观察到安全性担忧;E4/DRSP组与安慰剂组之间止血参数超出参考范围的参与者比例差异很少。
关键数值与推荐
- 主要结局为最严重盆腔痛VAS评分从基线至确证研究期结束6个治疗周期时的变化。
- E4/DRSP组VAS评分平均变化-33.2 mm,组间差异-8.5 mm(双侧95%CI -16.1至-0.9 mm)。
- E4/DRSP组VAS下降≥30%应答率53.2%,安慰剂组29.6%;下降≥50%应答率36.4%,安慰剂组12.3%。
临床怎么用
- 雌四醇/屈螺酮周期方案(24天用药+4天安慰剂)治疗6个周期可有效缓解子宫内膜异位症相关疼痛并改善妇科所见。
- 雌四醇/屈螺酮可能是治疗子宫内膜异位症的一种安全新选择,且可能降低血栓栓塞事件风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis. DESIGN: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. SETTING: Twenty-five study centers in Japan. PATIENT(S): A total of 162 Japanese women diagnosed with endometriosis. INTERVENTION(S): Participants were randomly allocated to the E4/DRSP group or the placebo group. In the E4/DRSP group, participants were orally administered one tablet containing E4 (15 mg) and DRSP (3 mg) daily for 24 days, followed by one placebo tablet for 4 days for a hormone-free interval, constituting a 1-cycle regimen. One placebo tablet was administered once daily for 28 days to participants in the placebo group. The treatments were continued for six cycles (24 weeks) throughout the confirmatory period. MAIN OUTCOME MEASURE(S): Changes in visual analogue scale (VAS) scores for the most severe pelvic pain (lower abdominal and back pain) from baseline to six treatment cycles at the end of the confirmatory study period. RESULT(S): Estetrol/drospirenone showed changes in the mean VAS scores for the most severe pelvic pain (-33.2 mm) from baseline to the end of the 6-cycle treatment. The between-group difference was significant (-8.5 mm; 2-sided 95% confidence interval, -16.1 to -0.9 mm), showing superiority to placebo. The responder rates, ≥30% and ≥50% reductions in the VAS scores from baseline, were higher in the E4/DRSP group than in the placebo group: 53.2% vs. 29.6% and 36.4% vs. 12.3%. Objective gynecological findings (induration of the cul-de-sac, pelvic tenderness, and limited uterine mobility) were significantly improved by E4/DRSP treatment, and the proportions of stable and worsened participants were significantly lower than in the placebo group. Estetrol/drospirenone decreased the size of endometriomas and improved quality of life, on the basis of quality of life-related questionnaires and global impression scores. No safety concerns were observed with E4/DRSP treatment. Few differences were observed in the proportion of participants with hemostasis parameters outside the reference range between the E4/DRSP and placebo groups. CONCLUSION(S): Estetrol/drospirenone effectively treats endometriosis-associated pain and improves gynecological findings. Estetrol/drospirenone may be a safe, new option for endometriosis treatment with a potentially decreased risk of thromboembolic events. CLINICAL TRIAL REGISTRATION NUMBER: jRCT2011210027.
引用
- Harada T, Kobayashi T, Hirakawa A, et al. Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study. Fertil Steril. 2024. PMID: 39002879. doi:10.1016/j.fertnstert.2024.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。